{"id":"NCT01948193","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth","officialTitle":"Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given at 6, 10 and 14 Weeks of Age in Infants From India Who Previously Received a Dose of Hepatitis B Vaccine at Birth","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2014-12","completion":"2015-06","firstPosted":"2013-09-23","resultsPosted":"2015-09-25","lastUpdate":"2015-10-20"},"enrollment":177,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Whooping Cough","Hepatitis B","Poliomyelitis","Invasive Hib Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine","otherNames":["Hexaxim™"]}],"arms":[{"label":"Study Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to describe the immunogenicity and safety of a novel DTaP- IPV- Hep B-PRT\\~T fully liquid combined hexavalent vaccine (Hexaxim™) administered at 6, 10 and 14 weeks of age in infants born to mothers documented to be serum anti-hepatitis B surface antigen (HBsAg) serology negative in India.\n\nPrimary Objective:\n\n* To evaluate the immunogenicity of the study vaccine in terms of seroprotection \\[diphtheria toxoid, tetanus toxoid, poliovirus types 1, 2 and 3, Haemophilus influenzae type b (Hib) polysaccharide (PRP), hepatitis B (Hep B)\\] and vaccine response for pertussis antigens \\[pertussis toxoid (PT) and filamentous haemagglutinin (FHA)\\] one month after the third dose.\n\nSecondary Objectives:\n\n* To further describe the immunogenicity of the study vaccine, before the first dose and one month after the third dose.\n* To describe the safety after each and any doses of the study vaccine.","primaryOutcome":{"measure":"Percentage of Participants With Seroprotection After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial Oral Poliovirus Vaccine and Recombinant Hep B Monovalent Vaccine at Birth","timeFrame":"Pre-dose 1 to one month post-dose 3","effectByArm":[{"arm":"All Infants","deltaMin":99.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":2,"countries":["India"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":177},"commonTop":["Irritability","Injection site Tenderness","Crying abnormal","Upper respiratory tract infection","Injection site Swelling"]}}